• Something wrong with this record ?

HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release

T. Etrych, M. Sírová, L. Starovoytova, B. Ríhová, K. Ulbrich,

. 2010 ; 7 (4) : 1015-26.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

In this paper we describe the synthesis, physicochemical characteristics and data on the biological activity of polymer prodrugs based on the anticancer drugs paclitaxel (PTX) and docetaxel (DTX) conjugated with a water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer drug carrier. The drugs were derivatized and then attached to the polymer backbone via a spacer that is stable under physiological conditions (pH 7.4) and hydrolytically degradable in mild acidic environments (e.g., endosomes, pH approximately 5). Polymer-drug conjugates were designed to achieve prolonged blood circulation and release of the active compound in target cells. Six types of conjugates differing in the structure of the keto acid (levulic, 3-(acetyl)acrylic acid) and 4-(2-oxopropyl)benzoic acid-containing spacer or in the amount of drug bound to the HPMA copolymer were synthesized. In all the conjugates, the linkage susceptible to hydrolytic cleavage was formed by the reaction of the carbonyl group of a drug derivative with the hydrazide group-terminated side chains of the polymer. In vitro incubation of the conjugates in buffers resulted in much faster release of drugs or their derivatives from the polymer at pH 5 than at pH 7.4 with the rate depending on the detailed structure of the spacer. Conjugates containing drugs acylated with levulic acid were tested for their anticancer activity in vivo using two murine models. The PTX-containing conjugate showed better antitumor efficacy in the 4T1 model of mammary carcinoma than the parent drug and its derivative. The DTX-containing conjugate demonstrated high activity in treating EL4 T cell lymphoma. The treatment with the polymer conjugates was devoid of side toxicity. In both models, we achieved complete regression of established tumors accompanied by a durable tumor resistance in most of the cured animals.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026368
003      
CZ-PrNML
005      
20121210093712.0
007      
ta
008      
120817s2010 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1021/mp100119f $2 doi
035    __
$a (PubMed)20518512
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Etrych, Tomás $u Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic. etrych@imc.cas.cz
245    10
$a HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release / $c T. Etrych, M. Sírová, L. Starovoytova, B. Ríhová, K. Ulbrich,
520    9_
$a In this paper we describe the synthesis, physicochemical characteristics and data on the biological activity of polymer prodrugs based on the anticancer drugs paclitaxel (PTX) and docetaxel (DTX) conjugated with a water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer drug carrier. The drugs were derivatized and then attached to the polymer backbone via a spacer that is stable under physiological conditions (pH 7.4) and hydrolytically degradable in mild acidic environments (e.g., endosomes, pH approximately 5). Polymer-drug conjugates were designed to achieve prolonged blood circulation and release of the active compound in target cells. Six types of conjugates differing in the structure of the keto acid (levulic, 3-(acetyl)acrylic acid) and 4-(2-oxopropyl)benzoic acid-containing spacer or in the amount of drug bound to the HPMA copolymer were synthesized. In all the conjugates, the linkage susceptible to hydrolytic cleavage was formed by the reaction of the carbonyl group of a drug derivative with the hydrazide group-terminated side chains of the polymer. In vitro incubation of the conjugates in buffers resulted in much faster release of drugs or their derivatives from the polymer at pH 5 than at pH 7.4 with the rate depending on the detailed structure of the spacer. Conjugates containing drugs acylated with levulic acid were tested for their anticancer activity in vivo using two murine models. The PTX-containing conjugate showed better antitumor efficacy in the 4T1 model of mammary carcinoma than the parent drug and its derivative. The DTX-containing conjugate demonstrated high activity in treating EL4 T cell lymphoma. The treatment with the polymer conjugates was devoid of side toxicity. In both models, we achieved complete regression of established tumors accompanied by a durable tumor resistance in most of the cured animals.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a lymfom T-buněčný $x farmakoterapie $7 D016399
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methakryláty $x chemie $7 D008689
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a paclitaxel $x chemie $x farmakologie $7 D017239
650    _2
$a polymery $x chemická syntéza $x chemie $x farmakologie $7 D011108
650    _2
$a taxoidy $x chemie $x farmakologie $7 D043823
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sírová, Milada
700    1_
$a Starovoytova, L
700    1_
$a Ríhová, Blanka
700    1_
$a Ulbrich, Karel
773    0_
$w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 7, č. 4 (2010), s. 1015-26
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20518512 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121210093749 $b ABA008
999    __
$a ok $b bmc $g 948410 $s 783714
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 7 $c 4 $d 1015-26 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
LZP    __
$a Pubmed-20120817/10/04

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...